Kevin Kalinsky, MD, MS, on the RxPONDER Trial Methods

Video

In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.

In the phase 3 RxPONDER trial (NCT01272037), investigators evaluated the use of endocrine therapy versus chemotherapy followed by endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer with a recurrence score between 0 and 25.

Patients with HR–positive, HER2-negative, lymph node–positive breast cancer have an increased risk of recurrence and are typically treated with chemotherapy. Therefore, to prevent potential overtreatment or undertreatment, the 21-gene Oncotype Dx Recurrence Score is used to identify which patients with these disease characteristics can omit chemotherapy.

Investigators launched the RxPONDER trial, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy. CancerNetwork® spoke with Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine as well as director of the Glenn Family Breast Center and director of breast medical oncology at Winship Cancer Institute of Emory University, about the trial and its methods.

Transcription:

We prespecified the analysis to look at whether there was a difference in effect for those patients who are postmenopausal versus pre[menopausal]. And there was a separate landmark study called the TAILORx trial [NCT00310180] for patients who had [lymph] node–negative breast cancer, but the same subtype, hormone receptor–positive and -negative [breast cancer]. And they saw in an exploratory analysis that there was a difference depending upon age. I think that when we look at menopausal status, I’m not sure if we were surprised. I think we’re surprised at how different the populations work.

Recent Videos
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
Related Content